Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Presentations at the 24th Congress of the European Hematology Association

NEWTOWN, Pa., June 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
May 28, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Presentations at Three Upcoming Conferences

NEWTOWN, Pa., May 28, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
May 14, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Reports Business Highlights and First Quarter 2019 Financial Results

NEWTOWN, Pa., May 14, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
May 13, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces License Agreement with HanX Biopharmaceuticals to Develop and Commercialize Rigosertib in Greater China

Onconova to Receive $4 Million Upfront, including $2 Million Fee and $2 Million for Onconova Shares Purchased at a Premium, Plus up to $45.5 Million in Regulatory and Sales Milestones for Rigosertib...
May 07, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2019 Financial Results

NEWTOWN, Pa., May 07, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
May 06, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics Announces Presentations at the 15th International Symposium on Myelodysplastic Syndromes (MDS 2019) in Copenhagen, Denmark

NEWTOWN, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
April 02, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present Update at the 2019 HCW Global Life Sciences Conference in London, April 7-9

NEWTOWN, Pa., April 02, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...
March 26, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. Reports Business Highlights and Full Year 2018 Financial Results

NEWTOWN, Pa., March 26, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug...
March 25, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Achieves Over 75 Percent of Planned Enrollment in Pivotal Phase 3 INSPIRE Study of Rigosertib in Myelodysplastic Syndromes

Full enrollment of 360 patients anticipated in second half of 2019Pivotal global study continues enrolling worldwide Potential for first new therapy in 15 years to address unmet medical need in MDS ...
March 19, 2019 07:30 ET | Source: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2018 Financial Results

NEWTOWN, Pa., March 19, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat...